| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a27502da51e5a4348577b88b1ca3fb66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e360b5742fcce54287401b334b6c66c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-385 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0657
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0619
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0618
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
| filingDate |
2011-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6107eff6e0b35765708d480af4840703 |
| publicationDate |
2014-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8716017-B2 |
| titleOfInvention |
Technologies, methods, and products of small molecule directed tissue and organ regeneration from human pluripotent stem cells |
| abstract |
Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces specification of neuroectoderm direct from the pluripotent state of hESCs and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces specification of cardiomesoderm direct from the pluripotent state of hESCs and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. This invention enables well-controlled efficient induction of pluripotent hESCs exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021232062-A1 |
| priorityDate |
2010-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |